MRC Technology and AICR Partnership Reports Success for Cancer Research
Published: Feb 26, 2013
Over the year, MRC Technology’s experts reviewed and monitored 25 priority projects from AICR’s overall portfolio, advising on development and commercialisation as appropriate.
For three of these projects, MRC Technology negotiated revenue share agreements on behalf of AICR with the universities holding the grants. Each of these agreements reflects the value of the support given by AICR towards the success and commercialisation of the research.
Mike Johnson, MRC Technology’s Director of Corporate Partnerships commented: “The success of this relationship is based on the ability of MRC Technology to add value to AICR’s mission, ensuring that research funded by the organisation creates potential new health benefits wherever possible. We look forward to continuing our work with AICR, and to building similar partnerships with other charities and universities.”
Dr Helen Rippon, Head of Science at AICR commented, “We very much value our partnership with MRC Technology, and recognise their expertise in managing and commercialising IP. We are a small team at AICR, and only through our partnership with MRC Technology can we ensure that opportunities are not missed for AICR-funded research to be steered towards patient benefit. We have found their open, honest and regular communication and flexibility to be of great benefit through the past year. We look forward to continuing the relationship and further realising returns on AICR-funded research for people affected by cancer”
Phone: +44 (0) 7771 730919
At MRC Technology
Marketing & Communications Officer
Phone: +44 (0)20 7391 2798
About MRC Technology
MRC Technology (www.mrctechnology.org) is a technology transfer company responsible for adding commercial value to cutting edge scientific discoveries through strategic patent protection, creative licensing of intellectual property (IP), partnered research or further scientific development.
As well as offering technology transfer services to the UK’s Medical Research Council the Company has recently broadened its activity to include helping other charitable and academic organisations (such as AICR) with IP management and commercial development of healthcare-related science, thus bringing valuable income back to the organisations to help fund further research.
MRC Technology also has small molecule drug discovery and therapeutic antibody facilities, providing lead-stage therapeutic assets to pharmaceutical and biotechnology companies.
AICR receives no government grants and relies totally on fundraising for its income. Unlike many UK-based charities, AICR does not confine its support to within this country. It is the leading charity funding cancer research anywhere in the world. AICR currently funds 182 active projects: 76 in the UK and 106 Overseas. That’s 178 scientists, across 18 countries. The cost of this research is £ 34,677,781. AICR's overall spend on research to date is £159,047,292 - on 1882 projects throughout 32 different countries.
The 18 countries currently holding grants are: Australia (13); Canada (2); Denmark (3); Finland (1); France (8); Germany (5); Greece (3); Israel (4); Italy (25); Netherlands (13); Portugal (1); Spain (15); Sweden (2); Switzerland (5); USA (6); UK:- England (58); Scotland (15); Wales (3).
For further information about AICR’s work or to find out how to support the charity, please call 01334 477910 or visit www.aicr.org.uk. Follow us on Facebook and Twitter.